Interstitial Cystitis in Black Women: Bladder Pain, Not UTI

If you have been treated for six urinary tract infections in two years and the cultures kept coming back clean, the antibiotics were never the answer. Interstitial cystitis, also called bladder pain syndrome, produces every symptom of a UTI without the bacteria: urgency, frequency, and pain in the bladder or pelvis that gets worse as the bladder fills and eases for a while after you urinate. The American Urological Association defines it as pelvic pain and lower urinary tract symptoms lasting more than six weeks with no infection or other identifiable cause. A negative culture in someone with UTI-like symptoms is not a clean bill of health. It is the finding that should redirect the entire workup.

Interstitial cystitis and bladder pain syndrome (IC/BPS) are the same condition under two names. The bladder wall becomes persistently painful and hypersensitive. The National Institute of Diabetes and Digestive and Kidney Diseases describes the core experience as "pain in the bladder that worsens until you urinate and then improves for a little while," plus frequent urination and urgency that can arrive before the bladder has had time to fill.

That filling-and-emptying pattern is what separates IC/BPS from an infection. A bacterial UTI hurts on a different schedule: burning during urination, often with fever or flank pain when it moves upward. IC/BPS pain is pressure that accumulates, and voiding is the only thing that turns the volume down. That is also why it gets misread as overactive bladder, which is an urgency problem without the pain signature.

The most common path into IC/BPS runs through years of presumed UTIs. Symptoms match, a clinician prescribes an antibiotic, the culture returns negative, and nobody circles back. The next flare gets another prescription. The AUA guideline is blunt about what should not happen next: "Long-term oral antibiotic administration should not be offered." That is a Grade B Standard, its strongest form of a do-not recommendation.

The scale of the miss is measurable. In the RAND Interstitial Cystitis Epidemiology study, which screened 12,752 completed questionnaires drawn from more than 130,000 adult women, between 2.70% and 6.53% met symptom criteria depending on the case definition, roughly 3.3 to 7.9 million US women. Almost none of them knew it.

The problem runs in both directions. When researchers reviewed 1,334 charts carrying an IC/BPS diagnosis code in a national Veterans Affairs cohort, only 48.8% of those patients actually met diagnostic criteria. The label is applied loosely to some people and withheld for years from others. If you have been told it is "just recurrent UTIs," ask why the cultures are negative.

Prevalence research on IC/BPS has under-enrolled Black women badly enough that no honest claim can be made about how common the condition is in Black communities. The 2025 internet survey of 1,631 people with IC/BPS was 88.4% white and 6.0% Black. The landmark amitriptyline trial was 74% white. What that research does document, consistently, is a gap in who gets diagnosed and who gets treated.

In that same 2025 survey, respondents who identified as a racial minority or multiple races were significantly less likely to hold a formal medical diagnosis after adjustment for age, symptom duration, and insurance. They were also treated differently once in the system.

Under-referral to physical therapy sits on top of a well-documented problem with how Black patients' pain is received. In a 2016 study in the Proceedings of the National Academy of Sciences, half of a sample of white medical students and residents endorsed at least one false belief about biological differences between Black and white people, such as thicker skin or less sensitive nerve endings. Those who endorsed those beliefs rated Black patients' pain lower and made less accurate treatment recommendations. IC/BPS has no imaging finding and no blood test. It is diagnosed almost entirely on the strength of a pain report, which makes it precisely the condition where that bias does the most damage. We have written more on what the evidence shows about pain discounting in Black patients.

The delay is not new. A 1993 case series from a Boston urology practice found that minority women had symptoms for an average of 2.9 years before diagnosis. It included only 17 minority patients out of 201, so it establishes that the problem was documented three decades ago, not its current size.

There is no confirmatory test. The AUA guideline calls for "a careful history, physical examination, and laboratory examination to document symptoms and signs that characterize IC/BPS and exclude other disorders," with baseline pain and voiding symptoms recorded so treatment effects can be measured against them. NIDDK describes the same approach: clinicians diagnose IC by ruling out other conditions with similar symptoms.

What that looks like in practice: urinalysis and urine culture to settle the infection question, a pelvic exam that includes palpating the pelvic floor muscles for tenderness (this step drives the treatment decision and is skipped constantly), and consideration of bladder cancer, stones, endometriosis, and other pelvic pain generators. Cystoscopy is used selectively, including to identify Hunner lesions, a subtype with its own treatment path. Bring a three-day voiding diary with pain scores. It converts a vague history into a document, and a document is harder to wave off.

The 2022 AUA guideline abandoned the old first-line through sixth-line ladder. Treatment is now grouped by type, chosen against a patient's specific presentation. The evidence grades still tell you where to start.

The guideline states that appropriate manual physical therapy techniques should be offered to patients who present with pelvic floor tenderness, at Evidence Strength Grade A. No drug, instillation, or procedure in the guideline carries that grade. The trial behind it randomized women with IC/BPS and pelvic floor tenderness across 11 North American centers to 10 sessions of myofascial physical therapy or general therapeutic massage: 59% of the myofascial physical therapy group reported moderate or marked improvement, against 26% with massage.

This is internal manual work on the pelvic floor muscles by a therapist trained in it, not Kegels. Kegels ask a muscle to contract, and in IC/BPS that muscle is usually already too tight. Ask for a referral to a pelvic floor physical therapist by name. If a clinician offers a drug before offering this, that is the moment to push. Our guide to what pelvic floor therapy involves covers what a first appointment looks like.

The guideline treats self-care and behavioral modification as a clinical principle to discuss with every patient. Diet is the highest-yield piece and costs nothing. In a study of 104 patients rating 175 foods and beverages, the items reported most often as triggers were coffee, tea, soda, alcohol, citrus fruits and juices, artificial sweeteners, and hot pepper. Triggers are individual. Remove the common offenders, stabilize, then reintroduce one at a time while logging symptoms. Blanket elimination diets are how people end up malnourished and no better.

Amitriptyline, cimetidine, hydroxyzine, and pentosan polysulfate are listed as options, at Grades B, B, C, and B. "Option" is the weakest recommendation category the guideline has. The amitriptyline trial illustrates why: across 271 randomized patients, 55% responded on the drug and 45% on placebo, a difference that did not reach significance. Pentosan polysulfate carries a specific warning. The guideline directs clinicians to counsel patients about the risk of macular damage and vision injury, after a 2018 Ophthalmology case series identified a pigmentary maculopathy linked to chronic exposure. If you take it, you need a baseline retinal exam and an ophthalmologist following you.

Bladder instillations (DMSO, heparin, lidocaine) place medication directly into the bladder through a catheter and are a reasonable next step when behavioral work and physical therapy are not enough. Four things the guideline says should not be offered: long-term oral antibiotics, intravesical BCG outside a research study, high-pressure long-duration hydrodistension, and long-term oral steroids. If any of these are proposed to you, ask the clinician to justify it against the guideline.

IC/BPS is frequently one part of a broader pain picture, which is another reason a clinician looking only at the bladder misses it. In a study of 205 women with IC/BPS, 38.6% also had irritable bowel syndrome, 17.7% had fibromyalgia, and 9.5% had chronic fatigue syndrome. Pain, depression, and sleep disruption all worsened as the number of overlapping conditions rose. In a separate cohort of 533 IC/BPS patients, 20.3% reported a history of endometriosis.

Endometriosis matters here for a practical reason: both conditions produce pelvic pain, both are diagnosed late, and treating one while ignoring the other leaves a patient still in pain and told nothing worked. If you have painful periods alongside bladder pain, say both out loud in the same appointment.

Ask your primary care clinician for copies of every urine culture result from the past two years. Negative cultures beside documented symptoms are the strongest argument you can bring. Ask for a referral to a urologist or urogynecologist, and separately ask for a referral to a pelvic floor physical therapist, since the second does not always follow the first.

Being believed is part of the treatment. If your pain has been dismissed more than once, you can find a Black urologist, urogynecologist, or pelvic floor physical therapist in our directory and start with a clinician who takes the report seriously the first time.